Labcorp (LH) has announced that it has received De Novo marketing authorization from the FDA for PGDx elio™ plasma focus Dx, the only kitted, pan-solid tumor liquid biopsy test available. This test is a significant addition to the company's precision oncology portfolio.
Shakti Ramkissoon, Vice President and Medical Lead for Oncology at Labcorp, stated, "This new liquid biopsy test offers laboratories and oncologists a convenient, cost-effective, and highly targeted tumor profiling solution applicable to a broad spectrum of solid tumor types, especially in scenarios where tumor tissue is limited or unavailable."
